Clinical trial NCT01478178: Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Official title: Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Glioma
Glioblastoma
Glioblastoma Multiforme
GBM
Brain Cancer
Keywords: Glioma
Glioblastoma
Glioblastoma multiforme
GBM
brain tumor
brain cancer
recurrent brain tumor
recurrent brain cancer
refractory brain tumor
refractory brain cancer
recurrent GBM
refractory GBM
recurrent glioma
refractory glioma
recurrent glioblastoma
refractory glioblastoma
recurrent glioblastoma multiforme
refractory glioblastoma multiforme
failed temodar
failed temozolomide
temodar refractory
temozolomide refractory
failed avastin
avastin refractory
failed bevacizumab
bevacizumab refractory
avastin failure
bevacizumab failure
temodar failure
temozolomide failure
Lead sponsor: Kintara Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2011-11-23
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.

Detailed description: Recurrent glial tumors of the brain continue to be one of the most challenging malignancies to treat. Median survival for patients with recurrent disease is approximately 6 months for glioblastoma multiforme. Bevacizumab is used for treatment of recurrent disease; however patients who fail bevacizumab do not have many treatment options.

Metastases to the brain are the most common intracranial tumors in adults and occur ten times more frequently than primary brain tumors. It is estimated that 8 - 10% of cancer patients may develop symptomatic metastatic tumors in the brain. Systemic therapy is rarely used for primary treatment of brain metastases because many tumors that metastasize to the brain are not chemosensitive or have been already heavily pretreated with potentially effective agents, and poor penetration through the blood brain barrier is an additional concern.

Dianhydrogalactitol (DAG) rapidly penetrates both the cerebrospinal fluid (CSF) and the blood-brain barrier and accumulates in brain tissue. Clinical study of DAG in patients with GBM or with progressive secondary brain tumors is warranted. Patients with secondary brain metastases were allowed to enroll into the current protocol in Cohorts 2 and 3; however, enrollment ceased with Amendment 5 and will not be continued beyond Cohort 3.

This study will utilize a standard 3 + 3 dose escalation design, until the MTD or the maximum specified dose has been reached. In Phase 2, additional patients with GBM will be treated at the MTD (or other selected optimum Phase 2 dose) to measure tumor responses to treatment.

Eligibility criteria: Inclusion Criteria:

* Patients must be greater than or equal to 18 years old.
* Histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (glioblastoma), now recurrent; or Cohorts 2 and 3 only: progressive secondary brain tumor, has failed standard brain radiotherapy, and has brain tumor progression after at least one line of systemic therapy. Patients with progressive secondary brain tumors will not be enrolled under this protocol following the completion of Cohort 3.
* If GBM, previously treated for GBM with surgery and/or radiation, if appropriate, and must have failed both bevacizumab (Avastin) and temozolomide (Temodar), unless either or both are contraindicated.
* If GBM, greater than or equal to 12 weeks from radiotherapy, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field.
* Cohorts 2 \& 3 only: Patients with secondary brain tumors must be greater than or equal to 4 weeks from radiotherapy. Patients with progressive secondary brain tumors will not be enrolled under this protocol following the completion of Cohort 3.
* At least 4 weeks from last chemotherapy or bevacizumab (Avastin) therapy (6 weeks for nitrosourea or mitomycin C), or for chemotherapy regimes given continuously or on a weekly basis with limited potential for delayed toxicity, at least 2 weeks from last dose.
* At least 21 days or 5 half-lives (whichever is shorter) since prior investigational anti-cancer drugs. A minimum of 10 days between termination of the investigational drug and administration of DAG is required
* Recovered from all treatment-related toxicities to Grade 1 or less.
* Must have a Karnofsky performance status of \> 50 with a predicted life expectancy of at least 12 weeks.
* Must have known MGMT methylation and IDH1 mutation status to be screened for study entry.

Exclusion Criteria:

* Current history of neoplasm other than the entry diagnosis. Patients with previous cancers treated and cured with local therapy alone may be considered with approval of the Medical Monitor.
* Evidence of leptomeningeal spread of disease.
* Evidence of recent hemorrhage on baseline MRI of the brain.
* Concurrent severe, intercurrent illness.
* History of severe cardiac disease.
* Significant vascular disease.
* History of stroke or transient ischemic attack within 6 months prior to beginning treatment.
* Concomitant medications that are known inducers of CYP.
* Concomitant medications that are strong inhibitors of cytochrome P450 and CYP3A up to 14 days before Cycle 1 Day 1 (pimozide, diltiazem, erythromycin, clarithromycin, and quinidine, and amiodarone up to 90 days before)
* Known to be HIV positive or to have an AIDS-related illness.
* Pregnant or breast feeding.

Primary outcomes:
measure: Determination of maximum tolerated dose (MTD)
timeFrame: Study Day 35
Secondary outcomes:
measure: Evaluate tumor response in patients with recurrent malignant glioma
timeFrame: Every 60 days
measure: Characterization of Cycle 1 plasma pharmacokinetics
timeFrame: Cycle 1: 0, 0.25, 0.5, 1, 2, 4, 6 hrs and immediately prior to Cycle 1, Day 2 dosing
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco, Division of Neuro-Oncology
state: California
city: Denver
country: United States
facility: Sarah Cannon Research Institute
state: Colorado
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
Study officials:
affiliation: Sarah Cannon Research Institute; Nashville, Tennessee 37203, USA
name: Howard A Burris, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Florida Cancer Specialists, Sarasota, Florida 34232, USA
name: Manish Patel, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco, 94143, USA
name: Nicholas Butowski, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic, Rochester, Minnesota 55905, USA
name: Sani Kizilbash, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Sarah Cannon Research Institute; Denver, Colorado 80218 USA
name: Gerald Falchook, M.D.
role: PRINCIPAL_INVESTIGATOR
References: